linagliptin

(redirected from Trajenta)
Also found in: Medical.

lin·a·glip·tin

 (lĭn′ə-glĭp′tn)
n.
An oral hypoglycemic drug, C25H28N8O2, used to treat type 2 diabetes.

[lina-, of unknown origin + -gliptin, hypoglycemic drug suffix; see saxagliptin.]
Mentioned in ?
References in periodicals archive ?
Christian Boehringer, Chairman of the Shareholders' Committee says: 'Innovative medicines like SPIRIVA and OFEV for respiratory as well as JARDIANCE and TRAJENTA in diabetes have substantially improved therapy options for patients.
M2 PHARMA-June 12, 2019-Full Data from CAROLINA Outcome Trial Support Long-Term Cardiovascular Safety Profile of Trajenta
Medication Dosage and frequency Cynt 4 mg 1 tablet once daily Isoptin 240 mg 1 tablet once daily Aspicor 81 mg 1 tablet once daily Silosin 8 mg 1 tablet once daily Trajenta 5 mg 1 tablet once daily
Those approved in the United States are alogliptin (Nesina), linagliptin (Trajenta), saxagliptin (Onglyza), and sitagliptin (Januvia).
The DPP-IV inhibitors approved in the United States are alogliptin (Nesina), linagliptin (Trajenta), saxagliptin (Onglyza), and sitagliptin (Januvia).
The researchers maintained all patients on their metformin dosage and randomized them to any of five treatment arms--10 mg daily of the SGLT2 inhibitor empagliflozin (Jardiance), 25 mg daily empagliflozin, 5 mg daily of the DPP-4 inhibitor linagliptin (Trajenta), and two combination regimens: 5 mg linagliptin and 10 mg empagliflozin, and 5 mg linagliptin and 25 mg empagliflozin.
These revenue declines are expected to be partially offset by growth from a portfolio of other products including Humalog, Trajenta, Cialis, Forteo and Alimta, as well as the animal health business.
Linagliptin (5 mg, once-daily) is marketed in the US as Tradjenta (linagliptin) tablets, as Trajenta across Europe and Canada, and Trazenta in Japan, as well as in further markets.
M2 PHARMA-February 15, 2019-Boehringer Ingelheim and Lilly's CAROLINA Cardiovascular Outcome Trial for Trajenta Meets Primary Endpoint of Non-Inferiority Compared to Glimepiride
Sales in Endocrinology increased 25 percent primarily driven by growth of Trulicity, Basaglar, Forteo, Jardiance, and Trajenta. Oncology grew 2 percent primarily due to higher volumes for Lartruvo and Cyramza, partially offset by lower volumes for Alimta, and Immunology grew due to higher volumes for Taltz.